The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tesaro, Inc. (“Tesaro” or “the Company”) (NASDAQ:...
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tesaro, Inc. (“Tesaro” or “the Company”) (NASDAQ:...
WALTHAM, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that, pursuant to the terms of the indenture (the...
This article is being republished as part of our daily reproduction of WSJ.com articles that also appeared in the U.S. print edition of The Wall Street Journal (December 4, 2018). Global stocks...
Deal for Tesaro thrusts British company into highly competitive arena By Denise Roland and Kimberly Chin This article is being republished as part of our daily reproduction of WSJ.com articles...
The story "GlaxoSmithKline to Acquire Tesaro for $4.16 Billion--Update," published at 11:25 a.m. ET, incorrectly stated Glaxo expects results of a trial that could expand Zejula's...
By Kimberly Chin GlaxoSmithKline PLC on Monday said it would buy cancer-focused drug company Tesaro Inc. for about $4.16 billion, positioning the health-care giant in a promising, but fiercely...
10:03 ET - GlaxoSmithKline falls more than 7% on the New York Stock Exchange after announcing the purchase of a cancer biotech. Glaxo says it will pay $5.1B for Tesaro, which sells a cancer drug...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.